Last €4.46 EUR
Change Today -0.144 / -3.13%
Volume 0.0
RN3 On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 6:18 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

arena pharmaceuticals inc (RN3) Snapshot

Open
€4.50
Previous Close
€4.60
Day High
€4.50
Day Low
€4.46
52 Week High
05/29/13 - €7.08
52 Week Low
11/1/13 - €2.98
Market Cap
977.9M
Average Volume 10 Days
253.2
EPS TTM
--
Shares Outstanding
219.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARENA PHARMACEUTICALS INC (RN3)

arena pharmaceuticals inc (RN3) Related Businessweek News

No Related Businessweek News Found

arena pharmaceuticals inc (RN3) Details

Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight management in adults. Its products under development include APD811, an agonist of the prostacyclin receptor, which has completed single- and multiple-ascending dose Phase I trials for the treatment of pulmonary arterial hypertension; and temanogrel, an inverse agonist of the serotonin 2A receptor for the treatment of thrombotic diseases, which has completed single- and multiple-ascending dose Phase I trials. The company’s products under development also comprise APD334, an agonist of the sphingosine 1-phosphate subtype 1 receptor for the treatment of conditions related to autoimmune diseases, which has completed Phase I single-ascending dose trial; and APD371, an agonist of the cannabinoid receptor 2 that is in Phase I single-ascending dose trial for the treatment of pain. It also manufactures drug products under a manufacturing services agreement for Siegfried AG. The company was founded in 1997 and is based in San Diego, California.

310 Employees
Last Reported Date: 03/3/14
Founded in 1997

arena pharmaceuticals inc (RN3) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $690.0K
Co-Founder, Chief Scientific Officer, Executi...
Total Annual Compensation: $400.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $327.0K
Executive Vice President, General Counsel and...
Total Annual Compensation: $375.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $357.0K
Compensation as of Fiscal Year 2012.

arena pharmaceuticals inc (RN3) Key Developments

Arena Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013; Provides Earnings Guidance for the Year 2014

Arena Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter, the company recorded revenues of $6.516 million compared to $1.936 million a year ago. Net loss allocable to common stockholders was $23.459 million or $0.11 per basic and diluted share against $21.280 million or $0.10 per basic and diluted share a year ago. For the year, the company recorded revenues of $81.394 million compared to revenues of $27.587 million a year ago. Net loss allocable to common stockholders was $19.435 million or $0.09 per basic and diluted share against $88.301 million or $0.45 per basic and diluted share a year ago. For the year 2014, the company expects 2014 revenues of approximately $9.0 million from amortization of upfront payments from existing collaborations, approximately $7.0 million in development and patent reimbursements from Eisai, and approximately $1.0 million from manufacturing services for Siegfried. The company expects full year 2014 research and development expenses of approximately $90.0 million to $98.0 million, including non-cash expenses of approximately $9.0 million, and approximately $6.0 million in development expenses reimbursed by Eisai and included in revenue. In addition, the company expects to spend approximately $9.0 million to $10.0 million in capital expenditures, primarily related to its manufacturing facility in Switzerland.

Arena Pharmaceuticals, Inc., Q4 2013 Earnings Call, Feb 27, 2014

Arena Pharmaceuticals, Inc., Q4 2013 Earnings Call, Feb 27, 2014

Arena Pharmaceuticals, Inc. to Report Q4, 2013 Results on Feb 27, 2014

Arena Pharmaceuticals, Inc. announced that they will report Q4, 2013 results at 5:00 PM, Eastern Standard Time on Feb 27, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RN3:GR €4.46 EUR -0.144

RN3 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ARIAD Pharmaceuticals Inc $7.22 USD +0.125
Array BioPharma Inc $3.80 USD -0.0399
Rigel Pharmaceuticals Inc $3.20 USD 0.00
Spectrum Pharmaceuticals Inc $6.80 USD -0.08
Vivus Inc $5.33 USD +0.08
View Industry Companies
 

Industry Analysis

RN3

Industry Average

Valuation RN3 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 16.9x
Price/Book 15.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 13.4x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARENA PHARMACEUTICALS INC, please visit www.arenapharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.